Version 1
: Received: 18 July 2023 / Approved: 19 July 2023 / Online: 20 July 2023 (02:49:03 CEST)
How to cite:
Tian, C.; Ziegler, J. N.; Zucker, I. Extracellular Vesicle microRNAs in Heart Failure: Pathophysiological Mediators and Therapeutic Targets. Preprints2023, 2023071285. https://doi.org/10.20944/preprints202307.1285.v1
Tian, C.; Ziegler, J. N.; Zucker, I. Extracellular Vesicle microRNAs in Heart Failure: Pathophysiological Mediators and Therapeutic Targets. Preprints 2023, 2023071285. https://doi.org/10.20944/preprints202307.1285.v1
Tian, C.; Ziegler, J. N.; Zucker, I. Extracellular Vesicle microRNAs in Heart Failure: Pathophysiological Mediators and Therapeutic Targets. Preprints2023, 2023071285. https://doi.org/10.20944/preprints202307.1285.v1
APA Style
Tian, C., Ziegler, J. N., & Zucker, I. (2023). Extracellular Vesicle microRNAs in Heart Failure: Pathophysiological Mediators and Therapeutic Targets. Preprints. https://doi.org/10.20944/preprints202307.1285.v1
Chicago/Turabian Style
Tian, C., Jessica N. Ziegler and Irving Zucker. 2023 "Extracellular Vesicle microRNAs in Heart Failure: Pathophysiological Mediators and Therapeutic Targets" Preprints. https://doi.org/10.20944/preprints202307.1285.v1
Abstract
Extracellular vesicles (EVs) are emerging mediators of intracellular and inter-organ communications in cardiovascular diseases (CVDs), especially in the pathogenesis of heart failure through the transference of EV-containing bioactive substances. microRNAs (miRNAs) are contained in EV cargo and are involved in the progression of heart failure. Over the past several years, a growing body of evidence has suggested that the biogenesis of miRNAs and EVs are tightly regulated, and the sorting of miRNAs into EVs is highly selective and tightly controlled. Extracellular miRNAs, in particular circulating EV-miRNAs, have shown promising potential as prognostic and diagnostic biomarkers for heart failure and as therapeutic targets. In this review, we summarize the latest progress concerning the role of EV-miRNAs in HF and their application in a therapeutic strategy development for heart failure.
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
